2006
Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC)
Pomerantz M, Manola J, Taplin M, Bubley G, Inman M, Lowell J, Kantoff P, Oh W. Phase II study of low dose (LD) and high dose (HD) premarin in androgen independent prostate cancer (AIPC). Journal Of Clinical Oncology 2006, 24: 4560-4560. DOI: 10.1200/jco.2006.24.18_suppl.4560.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerLow dosesHigh dosesLD armProgressive androgen-independent prostate cancerHD armMedian time to progressionClinical predictors of responseStudy of low doseGrade 3 toxicityPatients treated with LDProphylactic breast irradiationPSA response rateTime to progressionIndependent prostate cancerPhase II studyStage of accrualPredictors of responseCorrelates of treatment responseWarfarin 1 mgDose of PremarinBreast irradiationProphylactic warfarinTransdermal estradiolMedian PSA
2004
Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer
Oh W, Kantoff P, Weinberg V, Jones G, Rini B, Derynck M, Bok R, Smith M, Bubley G, Rosen R, DiPaola R, Small E. Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer. Journal Of Clinical Oncology 2004, 22: 3705-3712. PMID: 15289492, DOI: 10.1200/jco.2004.10.195.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAndrogensAnticoagulantsAntineoplastic Agents, HormonalAntineoplastic Agents, PhytogenicComplementary TherapiesCross-Over StudiesDiethylstilbestrolDisease ProgressionDrug ContaminationDrugs, Chinese HerbalEstradiol CongenersEthinyl EstradiolHumansMaleMiddle AgedProspective StudiesProstatic NeoplasmsReproducibility of ResultsTreatment OutcomeWarfarinConceptsAndrogen-independent prostate cancerPC-SPESProstate cancerEthinyl estradiolProstate-specific antigen declines >Prostate-specific antigen progressionMedian time to progressionRandomized phase II studyRandomized phase II trialMedian response durationTime to progressionIndependent prostate cancerPhase II studyPhase II trialCross-over phaseDES armProphylactic warfarinCross-over designII trialII studyThromboembolic eventsResponse durationClinical trialsPatientsDiethylstilbestrol
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply